Another Biopharmaceutical Production Base Settles in TEDA

An investment cooperation agreement has been recently inked between Uniongen Bioengineering (Suzhou) Co., Ltd. and TEDA Administrative Commission, and the company plans to build a modern biopharmaceutical production base in TEDA East. The project, with a total investment of 700 million RMB, covers an area of 28,000 square meters and will be constructed in two phases to produce Human Growth Hormone drugs. The first phase is scheduled to commence this year and is expected to reach an annual output value of 5 billion yuan after completion.

Uniongen is a comprehensive enterprise dedicated to innovative drug R&D and production of biological macromolecules. The company possesses advanced genetic engineering drug production and testing equipment, and has established a first-class R&D team. Leveraging the human serum albumin fusion protein technology platform, Uniongen independently developed multiple long-acting biologics for therapeutic purposes, which serve as the focal point of their comprehensive research endeavors.